Hytrin

Terazosin, the active ingredient in Hytrin, is a selective alpha‑1 adrenergic receptor antagonist presented as a tablet for oral use. It is used to treat hypertension and benign prostatic hyperplasia, helping lower blood pressure and improve urinary flow in adult patients.

GNH USA supplies Hytrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Terazosin is indicated for conditions involving the cardiovascular and urinary systems.

- Hypertension: reduces elevated blood pressure by causing vasodilation of peripheral vessels. - Benign prostatic hyperplasia (BPH): improves urinary flow by relaxing smooth‑muscle tone in the prostate and bladder neck.

Terazosin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Peripheral edema - Orthostatic hypotension

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism - Allergic reactions such as rash or angioedema - Liver enzyme elevations - Cardiac arrhythmia - Severe electrolyte disturbances

When prescribing Terazosin, clinicians should consider several safety measures.

- Initiate therapy at low dose: start with the lowest recommended dose to assess tolerance. - Monitor blood pressure: check regularly, especially after dose adjustments. - Assess renal function: adjust dosing if significant impairment is present. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Caution in patients with a history of orthostatic hypotension: monitor for dizziness. - Store at room temperature: keep in the original container, protect from moisture and light.

Terazosin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole) may increase plasma levels. - Co‑administration with other antihypertensives can cause additive hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) raise the risk of severe hypotension. - Lithium: concurrent use may raise lithium concentrations. - Aliskiren in diabetic patients: increased risk of renal impairment.

Moderate Interactions (Monitor Closely): - Diuretics: may affect electrolyte balance and blood pressure response. - NSAIDs: can blunt the antihypertensive effect. - Beta‑blockers: combined use may enhance bradycardia. - Other alpha‑blockers: cumulative vasodilatory effect. - Antidepressants with adrenergic activity: monitor for blood pressure changes.